Stock 4568 DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-06-07 am EDT 		5-day change 1st Jan Change
5,829 JPY +0.97% Intraday chart for Daiichi Sankyo Co., Ltd. +4.50% +50.54%
Jun. 04 Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May MT
Jun. 04 Transcript : Daiichi Sankyo Company, Limited - Special Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Daiichi Sankyo Buys Back Shares Worth Over 29 Billion Yen in May
MT
Transcript : Daiichi Sankyo Company, Limited - Special Call
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%
MT
Daiichi Sankyo : ASCO highlight briefing session materia
PU
Daiichi Sankyo : ASCO presentation materia
PU
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug
MT
Astra's Enhertu breast cancer trial shows 'unprecedented' results
RE
Astra's Enhertu delays breast cancer in patients with low HER2 levels
RE
Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified
RE
Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial
CI
AstraZeneca and Daiichi Sankyo Announce Positive Results from the DESTINY-Breast06 Phase III Trial Showed That ENHERTU Metastatic Breast Cancer and the Overall Trial Population
CI
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
BU
Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
AQ
RevolKa Signed Master Service Agreement with Daiichi Sankyo
AQ
RevolKa Signs Master Service Agreement with Daiichi Sankyo
CI
AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients
DJ
AstraZeneca, Daiichi Sankyo’s Lung Cancer Drug Shows Mixed Results in Late-stage Trial
MT
AstraZeneca's Lung Cancer Drug Shows Clinically Meaningful Improvement in Overall Survival
MT
Astra, Daiichi hail positive survival data for Dato-DXd
AN
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. News Daiichi Sankyo Co., Ltd.